Subscribe to Search results

Professor Hardisty indicated that he would like to switch to the heated NHS products for all patients, irrespective of their antibody status, as soon as supplies permitted.

Published on:

Great Ormond Street Hospital wrote to BPL, stating that many of the parents were very anxious about the use of commercial concentrate.

Published on:

Great Ormond Street Hospital was unable to locate any stored relevant documentation from the 1970s and 1980s (except individual patient records) to provide to the Inquiry, and there was no personal paperwork of Professor Hardisty's from the time to be found in storage.

Published on:

Dr Anna Pettigrew asserted in her statement to the Inquiry that the patients at Glasgow Yorkhill Haemophilia Centre would be transferred to Glasgow Royal Infirmary at 15-16.

Published on:

Dr Pettigrew noted that the commercial Factor VIII product was more 'user friendly' and dissolved more quickly than the SNBTS product.

Published on:

Minutes of the West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs which agreed to recommend to Dr Ala, the regional transfusion director, that NHS concentrate should be distributed in proportion to the number of patients treated.

Published on:

Minutes of the West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs where it was recommended that during the next 6 months all Centres should cut down on the use of Factor VIII and increase their usage of cryoprecipitate. Members agreed any shortfall would have to be met by increased purchasing of Commercial Factor VIII.

Published on:

Minutes of the West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs where there was reported to be an excess of cryoprecipitate. This was potentially attributed to overstocking in anticipation of a reduced supply of Factor VIII concentrate from BPL.

Published on:

Dr Mounir Wassef wrote to Dr Hill, outlining that one of his patents was exhibiting AIDS stigmata.

Published on:

Medical Report and Opinion was prepared regarding the treatment of Jonathan Buggins by G. F. Savidge

Published on:

Dr Savidge stated the administration of a large donor pool of commercial material in preference to cryoprecipitate without authorisation was negligent.

Published on:

Dr Savidge stated Armour concentrate was used exclusively in 1983 and 1984 with no reference to the available NHS concentrate at the hospital.

Published on:

Dr Savidge noted Dr Hill's view that continued use of the same batch confined the risk of infectivity but it was not practised on Johnathan Buggins. Between 1981 and mid-1984, he had been exposed to 20 different batches of Armour factor VIII.

Published on:

A report was produced by Professor Ingram, no evidence was found of any consideration being given to prioritising the child for NHS concentrate, or that consideration should have been given to no product in the place of commercial product.

Published on:

New Scientist published an article which referred to the possibility of AIDS being spread through Factor 8 concentrates.

Published on:

Dr Hill downplayed the risk of getting AIDS from using Factor VIII concentrate compared to the risk of arthritis by not using it.

Published on:

West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs supported the document prepared by the Reference Centres Directors on the effects of AIDS on the treatment of haemophiliacs.

Published on:

The commercial heat-treated Factor 8 product used at Birmingham Children's Hospital in 1985 and 1986 was Armour's product.

Published on:

Armour had been the sole supplier of heat-treated Factor 8 to the region up to the point at which it was discovered that previously HIV negative children at Birmingham Children's Hospital treated with heated Factorate had been infected with HIV.

Published on:

Armour made regular financial contributions to Dr Hill's "research fund".

Published on: